Top

Published in:

Open Access 01-12-2024 | Research

Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS)

Authors: Farzad Masoudkabir, Akbar Shafiee, Amirhossein Heidari, Negin Sadat Hosseini Mohammadi, Kiarash Tavakoli, Arash Jalali, Sepehr Nayebirad, Farshid Alaeddini, Soheil Saadat, Ali Vasheghani-Farahani, Saeed Sadeghian, Vicente Artola Arita, Mohamamdali Boroumand, Abbasali Karimi

Published in: BMC Psychiatry | Issue 1/2024

Abstract

Background

The prevalence and burden of substance and opium use have increased worldwide over the past decades. In light of rapid population changes in Tehran, we aimed to evaluate the prevalence of opium and other substance use among adult residents in Tehran, Iran.

Method

From March 2016 to March 2019, we utilized data from 8 296 participants in the Tehran Cohort Study recruitment phase (TeCS). We calculated the age-sex-weighted prevalence of substance use and the geographic distribution of substance use in Tehran. We also used logistic regression analysis to determine possible determinants of opium use.

Result

We analyzed data from 8 259 eligible participants with complete substance use data and the average age of participants was 53.7 ± 12.75 years. The prevalence of substance use was 5.6% (95% confidence interval [CI]: 4.6- 7.1%). Substance use was more common in males than females (Prevalence: 10.5% [95% CI: 8.6- 12.6%] vs. 0.5% [95% CI: 0.2- 1.2%], respectively). The age-sex weighted prevalence of substance use was 5.4% (95% CI: 4.6-7.1%). Moreover, opium was the most frequently used substance by 95.8% of substance users. Additionally, we found that male gender (Odds ratio [OR]: 12.1, P < 0.001), alcohol intake (OR: 1.3, P = 0.016), and smoking (OR: 8.5, P < 0.001) were independently associated with opium use.

Conclusions

We found that the prevalence of substance use in Tehran was 5.6%, and opium was the most frequently used substance. In addition, male gender, lower levels of education, alcohol, and tobacco consumption are the main risk factors for substance use in Tehran. Healthcare providers and policymakers can utilize our results to implement preventive strategies to minimize substance use in Tehran.

Network GBDC. Global burden of disease study 2017 (GBD 2017) results. Seattle, United States: Institute for health metrics and evaluation (IHME). 2018.

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.PubMedPubMedCentralCrossRef

Heidari N, Hajikarim-Hamedani A, Heidari A, Ghane Y, Sadat-Shirazi M-S, Ashabi G, Zarrindast M-R. Alcohol: Epigenome Alteration and Transgenerational Effect. In: Preprintsorg Preprints.org; 2023.

Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223–33.PubMedCrossRef

World Drug Report. 2023 [https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html].

Alcohol GBD, Drug Use C. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.CrossRef

Mohebbi E, Kamangar F, Rahimi-Movaghar A, Haghdoost AA, Etemadi A, Amirzadeh S, Najafi F, Shafeie F, Fakhari A, Ghaleban K, et al. An Exploratory Study of Units of Reporting Opium Usein Iran: implications for epidemiologic studies. Arch Iran Med. 2019;22(10):541–5.PubMed

Malloch-Brown M. Opium production in Afghanistan. BMJ. 2008;336(7651):972.PubMedPubMedCentralCrossRef

Jack H, Masterson AR, Khoshnood K. Violent conflict and opiate use in low and middle-income countries: a systematic review. Int J Drug Policy. 2014;25(2):196–203.PubMedCrossRef

10.

Soroosh D, Neamatshahi M, Zarmehri B, Nakhaee S, Mehrpour O. Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose. Subst Abuse Treat Prev Policy. 2019;14(1):8.PubMedPubMedCentralCrossRef

11.

Eskandarieh S, Jafari F, Yazdani S, Hazrati N, Saberi-Zafarghandi MB. Compulsory maintenance treatment program amongst Iranian injection drug users and its side effects. Int J High Risk Behav Addict. 2014;3(4):e21765.PubMedPubMedCentralCrossRef

12.

Sommers I, Baskin D, Baskin-Sommers A. Methamphetamine use among young adults: health and social consequences. Addict Behav. 2006;31(8):1469–76.PubMedCrossRef

13.

Shariatirad S, Maarefvand M, Ekhtiari H. Methamphetamine use and methadone maintenance treatment: an emerging problem in the drug addiction treatment network in Iran. Int J Drug Policy. 2013;24(6):e115–6.PubMedCrossRef

14.

Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. J Androl. 2012;33(4):515–28.PubMedCrossRef

15.

Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of Disease Study 2010. PLoS ONE. 2015;10(2):e0116820.PubMedPubMedCentralCrossRef

16.

Momtazi S, Noroozi A, Rawson R. An overview of Iran drug treatment and harm reduction programs. Textbook Addict Treatment: Int Perspect Milano: Springer 2015:543–54.

17.

Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, Hefazi M, Motevalian A. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016;111(10):1836–47.PubMedCrossRef

18.

Mohebbi E, Haghdoost AA, Noroozi A, Molavi Vardanjani H, Hajebi A, Nikbakht R, Mehrabi M, Jabbarinejad Kermani A, Salemianpour M, Baneshi MR. Awareness and attitude towards opioid and stimulant use and lifetime prevalence of the drugs: a study in 5 Large Cities of Iran. Int J Health Policy Manag. 2019;8(4):222–32.PubMedCrossRef

19.

Kok G, Gottlieb NH, Peters GJ, Mullen PD, Parcel GS, Ruiter RA, Fernández ME, Markham C, Bartholomew LK. A taxonomy of behaviour change methods: an intervention mapping approach. Health Psychol Rev. 2016;10(3):297–312.PubMedCrossRef

20.

Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, Abaie B, Islami F, Nasseri-Moghaddam S, Etemadi A. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ 2012, 344.

21.

Fallahzadeh MA, Salehi A, Naghshvarian M, Fallahzadeh MH, Poustchi H, Sepanlou SG, Gandomkar A, Malekzadeh R. Epidemiologic study of Opium Use in Pars Cohort Study: a study of 9000 adults in a rural Southern Area of Iran. Archives Iran Med (AIM) 2017, 20(4).

22.

Fleury MJ, Grenier G, Bamvita JM, Perreault M, Caron J. Predictors of alcohol and drug dependence. Can J Psychiatry. 2014;59(4):203–12.PubMedPubMedCentralCrossRef

23.

Moradinazar M, Najafi F, Jalilian F, Pasdar Y, Hamzeh B, Shakiba E, Hajizadeh M, Haghdoost AA, Malekzadeh R, Poustchi H, et al. Prevalence of drug use, alcohol consumption, cigarette smoking and measure of socioeconomic-related inequalities of drug use among Iranian people: findings from a national survey. Subst Abuse Treat Prev Policy. 2020;15(1):39.PubMedPubMedCentralCrossRef

24.

Heydari Z, Baneshi MR, Sharifi H, Zamanian M, Haji-Maghsoudi S, Zolala F. Evaluation of the treatment failure ratio in individuals receiving methadone maintenance therapy via the network scale up method. Int J Drug Policy. 2019;73:36–41.PubMedCrossRef

25.

Shokoohi M, Baneshi MR, Haghdoost A-A. Size estimation of groups at high risk of HIV/AIDS using network scale up in Kerman, Iran. Int J Prev Med. 2012;3(7):471.PubMedPubMedCentral

26.

Shafiee A, Saadat S, Shahmansouri N, Jalali A, Alaeddini F, Haddadi M, Tajdini M, Ashraf H, Omidi N, Masoudkabir F. Tehran cohort study (TeCS) on cardiovascular diseases, injury, and mental health: design, methods, and recruitment data. Global Epidemiol. 2021;3:100051.CrossRef

27.

Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, et al. Measurement of blood pressure in humans: A Scientific Statement from the American Heart Association. Hypertension. 2019;73(5):e35–e66.PubMedCrossRef

28.

Oraii A, Shafiee A, Jalali A, Alaeddini F, Saadat S, Masoudkabir F, Vasheghani-Farahani A, Heidari A, Sadeghian S, Boroumand M, et al. Prevalence, awareness, treatment, and control of type 2 diabetes mellitus among the adult residents of tehran: Tehran Cohort Study. BMC Endocr Disord. 2022;22(1):248.PubMedPubMedCentralCrossRef

29.

Oraii A, Shafiee A, Jalali A, Alaeddini F, Saadat S, Sadeghian S, Poorhosseini H, Boroumand M, Karimi A, Franco OH. Prevalence, awareness, treatment, and Control of Hypertension among adult residents of Tehran: the Tehran Cohort Study. Glob Heart. 2022;17(1):31.PubMedPubMedCentralCrossRef

30.

Shafiee A, Oraii A, Jalali A, Alaeddini F, Saadat S, Masoudkabir F, Tajdini M, Ashraf H, Omidi N, Heidari A, et al. Epidemiology and prevalence of tobacco use in Tehran; a report from the recruitment phase of Tehran cohort study. BMC Public Health. 2023;23(1):740.PubMedPubMedCentralCrossRef

31.

Carapetis J, Dadi AF. Erratum: Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet (2017) 390 (10100)(1211–1259)(S0140673617321542)(10.1016/S0140-6736 (17) 32154-2)). The Lancet 2017, 390(10106):e38.

32.

Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, Cocaine, and psychostimulants - United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.PubMedPubMedCentralCrossRef

33.

Moazen B, Shokoohi M, Noori A, Rahimzadeh S, Saeedi Moghaddam S, Rezaei F, Lotfizadeh M, Kazemi MR, Jamshidi HR, Pazhuheian F, et al. Burden of Drug and Alcohol Use disorders in Iran: findings from the global burden of Disease Study 2010. Arch Iran Med. 2015;18(8):480–5.PubMed

34.

Schalkoff CA, Lancaster KE, Gaynes BN, Wang V, Pence BW, Miller WC, Go VF. The opioid and related drug epidemics in Rural Appalachia: a systematic review of populations affected, risk factors, and Infectious diseases. Substance Abuse. 2020;41(1):35–69.PubMedCrossRef

35.

Azizi H, Buhler A, Bussink C, Campello G, Carpentier C, Eichinger N, Hariga F, Kamminga J, Korenblik A, Koutsenok I. The World Drug Report 2015. 2015.

36.

Kamali M, Tajadini H, Mehrabani M, Moghadari M. Consequences of opioid abuse and their treatments in Persian Medicine: a review study. Addict Health. 2020;12(1):46–57.PubMedPubMedCentral

37.

Naghavi M, Shahraz S, Sepanlou SG, Dicker D, Naghavi P, Pourmalek F, Mokdad A, Lozano R, Vos T, Asadi-Lari M, et al. Health transition in Iran toward chronic diseases based on results of global burden of Disease 2010. Arch Iran Med. 2014;17(5):321–35.PubMed

38.

Narenjiha HRH, Baghestani AR, et al. In: Tehran, editor. Rapid Assessment of Substance Abuse in Iran- second study. Center for Research and Education on abuse and substance abuse. Iran: University of Social Welfare and Rehabilitation Sciences, office of UN Proliferation Control Program; 2005.

39.

Noorbala AA, Saljoughian A, Bagheri Yazdi SA, Faghihzadeh E, Farahzadi MH, Kamali K, Faghihzadeh S, Hajebi A, Akhondzadeh S, Mousavi MT. Evaluation of drug and alcohol abuse in people aged 15 years and older in Iran. Iran J Public Health. 2020;49(10):1940–6.PubMedPubMedCentral

40.

Damari B, Sarami H, Alikhani S, Mirzaei H. A National survey on substance use among Iranian industrial workers. Med J Islam Repub Iran. 2020;34:20.PubMedPubMedCentral

41.

Noori R, Daneshmand R, Farhoudian A, Ghaderi S, Aryanfard S, Moradi A. Amphetamine-type stimulants in a group of adults in Tehran, Iran: a rapid situation assessment in twenty-two districts. Iran J Psychiatry Behav Sci 2016, 10(4).

42.

Sarani EM, Ahmadi J, Oji B, Mahi-Birjand M, Bagheri N, Bazrafshan A, Manshadi MD, Yaghoubi S, Dezhkam A, Khatami M, et al. Investigating the sequential patterns of methamphetamine use initiation in Iran. Subst Abuse Treat Prev Policy. 2020;15(1):52.PubMedPubMedCentralCrossRef

43.

44.

Yousefzadeh G, Sheikhvatan M. Age and gender differences in the clustering of metabolic syndrome combinations: a prospective cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS). Diabetes Metab Syndr. 2015;9(4):337–42.PubMedCrossRef

45.

Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.PubMedCrossRef

46.

Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of Disease Study 2010. Lancet. 2013;382(9904):1564–74.PubMedCrossRef

47.

Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, Abaie B, Islami F, Nasseri-Moghaddam S, Etemadi A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012;344:e2502.PubMedPubMedCentralCrossRef

48.

Ziaaddini H, Ziaaddini T, Nakhaee N. Pattern and trend of substance abuse in eastern rural Iran: a household survey in a rural community. J Addict. 2013;2013:297378.PubMedPubMedCentralCrossRef

49.

Ziaaddini H, Sharifi A, Nakhaee N, Ziaaddini A. The prevalence of at least one-time substance abuse among Kerman Pre-university Male Students. Addict Health. 2010;2(3–4):103–10.PubMedPubMedCentral

50.

Kheirkhah MT, Mokarrami M, Kazemitabar M, Garcia D. Inequalities in care for Iranian women suffering from the comorbidity of substance use and mental illness: the need for integrated treatment. Health Promot Perspect. 2023;13(3):198–201.PubMedPubMedCentralCrossRef

51.

Nolte-Troha C, Roser P, Henkel D, Scherbaum N, Koller G, Franke AG. Unemployment and substance use: an updated review of studies from North America and Europe. Healthc (Basel) 2023, 11(8).

52.

Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105–30.ADSPubMedPubMedCentralCrossRef

Title: Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS)
Authors: Farzad Masoudkabir
Akbar Shafiee
Amirhossein Heidari
Negin Sadat Hosseini Mohammadi
Kiarash Tavakoli
Arash Jalali
Sepehr Nayebirad
Farshid Alaeddini
Soheil Saadat
Ali Vasheghani-Farahani
Saeed Sadeghian
Vicente Artola Arita
Mohamamdali Boroumand
Abbasali Karimi
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2024
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-024-05561-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS)

Abstract

Background

Method

Result

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Result

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

The relationship between postpartum negative life events and postpartum depression: a moderated mediation model of neuroticism and psychological flexibility

A causal relationship between panic disorder and risk of alzheimer disease: a two-sample mendelian randomization analysis

A complex systems perspective on chronic aggression and self-injury: case study of a woman with mild intellectual disability and borderline personality disorder

The impact of depressive and anxious symptoms on non-suicidal self-injury behavior in adolescents: a network analysis

Associations between breakfast skipping and outcomes in neuropsychiatric disorders, cognitive performance, and frailty: a Mendelian randomization study

Network analysis on psychopathological symptoms, psychological measures, quality of life and COVID-19 related factors in Chinese psychiatric patients in Hong Kong